CA-VELO3D
20.10.2020 15:02:11 CEST | Business Wire | Press release
VELO3D , an innovator in digital manufacturing, announced the expansion of its systems portfolio to include Sapphire XC, an “Extra Capacity” large-format printer that will increase production throughput by 5X and reduce cost-per-part by up to 75%, when compared to the existing Sapphire system.
The company also announced plans to roll-out Sapphire Gen 2, which will be a software and hardware upgrade to the current system. Users can expect an improvement of anywhere between 10-50% in productivity and part-cost metrics when compared to the current Sapphire system. The Sapphire Gen 2 upgrade will be available to retrofit on all installed systems starting in Q2 2021.
The Sapphire product family now includes Sapphire Gen 2, the 1-meter tall Sapphire 1MZ and Sapphire XC—all using the laser powder-bed fusion (LPBF) process with patented capabilities to print without consideration of support structures. Sapphire systems specifically address the aerospace, power generation, and energy markets' unmet needs for quality-assured manufacturing of uncompromised geometries.
"Printing larger parts without the additive manufacturing constraints of support structures is highly attractive to many industrial end-users,” said Benny Buller, founder, and CEO of VELO3D . “For the first time, customers will be able to 3D-print uncompromised geometries, with the highest confidence in part quality, in a large format system. Quality assurance with large scale components is critical because the economic impact of failed builds is very significant. We have demonstrated that our integrated solution is capable of producing a greater yield of high-quality parts, and that foundational technology will transfer to our new Sapphire XC."
Sapphire XC Features
- Larger build volume: Build volume 600mm x 550 mm (compared to 315mm x 400 mm in Sapphire)
- Higher productivity for production: 8 lasers x 1,000W each (compared to 2 lasers x 1,000W in Sapphire)
- Integrated manufacturing process: Fully integrated with Flow™ pre-print software and Assure™ quality control software
- Consistent architecture: Utilizes the same optical-train design, recoater technology, gas-flow technology, and metrology as the current Sapphire. Users can also expect similar material properties as Sapphire
- Qualified material alloys : Compatible alloys include Aluminum F357, Titanium 6AI-4V, INCONEL® 718 and HASTELLOY® X
Sapphire XC Pre-Order
Delivery of Sapphire XC will begin in Q4 2021. Early pre-order of Sapphire XC secures a price and an early manufacturing slot for the system. Existing orders of Sapphire XC will consume all available manufacturing slots for Q4 ’21 and most of Q1 ’22.
Webinar Invitation
To learn more about the value of the Sapphire XC large format system and how it addresses unmet customer needs, register for an informative online fireside chat on Oct 22nd at 10 a.m. Eastern Standard Time. Scott Dunham, Vice President of Research at Smartech Analysis will moderate a discussion with Benny Buller, founder and CEO of VELO3D . Live Q&A from the audience will be included in the webinar.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201020005115/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
